SCHEMBL3559795

SCHEMBL3559795

COc1ccc(C=CC(=O)N2CC(CCl)c3c2cc([N+](=O)[O-])c2cc(C(=O)NCCO)ccc32)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.38
ALDH1A1 P00352 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 2/20 0.38
TP53 P04637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
BACE1 P56817 1/20 0.38
KMT2A Q03164 3/20 0.37
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
GPR183 P32249 3/20 0.35
APP P05067 1/20 0.35
MEN1 O00255 2/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3559792 1.00 MAPT (0.38) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL3563247 0.86 BACE1 (0.37) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL3563244 0.86 BACE1 (0.37) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL13853316 0.80 MAPK1 (0.34) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL5624641 0.77 ALDH1A1 (0.44) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL5624650 0.77 ALDH1A1 (0.44) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL3569771 0.77 P4HB (0.43) MAPTALDH1A1SMN1; SMN2LMNAL3MBTL1
SCHEMBL13853314 0.75 LMNA (0.45) MAPTALDH1A1SMN1; SMN2LMNAMAPK1
SCHEMBL14499189 0.75 ALDH1A1 (0.47) MAPTALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL3564263 0.74 BACE1 (0.45) MAPTALDH1A1LMNAL3MBTL1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US claimed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US claimed
US-7718688-B2 Nitrobenzindoles and their use in cancer therapy AUCKLAND UNISERVICES LIMITED (NZ) 2010-05-18 US disclosed
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization AUCKLAND UNISERVICES LIMITED (NZ) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119442-A1 as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization HIF1AN, HYOU1, HIF1A MAPT 4792/4885ALDH1A1 77/4885SMN1; SMN2 4797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.